Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

Texas MPN Workshop 2022 | The efficacy of ruxolitinib re-treatment in patients with MF

Aaron Gerds • 24 Aug 2022
Texas MPN Workshop 2022
Myelofibrosis Myeloproliferative Neoplasms Ruxolitinib

Aaron Gerds, MD, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, shares some insights into the safety and efficacy of re-treating patients with ruxolitinib as an alternative treatment approach in myelofibrosis (MF). This interview took place at the third annual Texas MPN Workshop (TMW) 2022, held in San Antonio, TX.

Disclosures

Consulting/Advisory for CTI Biopharma, GSK/Sierra Oncology, Morphosys, ParmaEssentia, Imago, AbbVie

More from Aaron Gerds

2:26
ACE-536-MF-001 update: luspatercept for the treatment of anemia in myelofibrosis
Aaron Gerds • 5 Jun 2023
1:22
Managing cytopenias following JAK inhibitor treatment & achieving true disease modification in MF
Aaron Gerds • 5 Jun 2023
2:20
MOMENTUM & the potential impact of approval of momelotinib in myelofibrosis
Aaron Gerds • 5 Jun 2023
13:31
Key highlights in MPNs: novel agents, combinations, and the potential role of immunotherapy
Aaron Gerds et al. • 12 Dec 2022

Related Videos

1:25
Highlights on myelofibrosis from ASH
Claire Harrison • 21 Dec 2018
3:07
Ruxolitinib plus azacitidine for myelofibrosis
Naval Daver • 18 Dec 2018
3:34
A RESPONSE to ruxolitinib: update on 4-year trial follow-up
Jean-Jacques Kiladjian • 2 Mar 2018
2:39
Targeting JAK2 V617F in MPNs with interferon alpha and arsenic trioxide
Jean-Jacques Kiladjian • 6 Dec 2018
The content of VJHemOnc is intended for healthcare professionals